Atherosclerosis versus arterial stiffness in advanced renal failure

Advances in Cardiology

Volumn 44, Issue , 2007, Pages 187-198

  Guerin, A ^a,b   Pannier, B ^a   London, G ^a  

^a Centre Hospitalier Manhes   (France)

^b Centre Hospitalier FH Manhes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY; ATHEROSCLEROSIS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; HUMAN; PATHOPHYSIOLOGY; PULSATILE FLOW; REVIEW; UREMIA; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ARTERIES; ATHEROSCLEROSIS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY FAILURE, CHRONIC; PULSATILE FLOW; UREMIA; VASCULAR RESISTANCE;

EID: 33751110214     PISSN: 00652326     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000096730     Document Type: Review

References (66)

1. Cheug AK, Sarnak MJ, Yan G: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353-362.
2. McCullough PA: Cardiorenal risk: an important clinical intersection. Rev Cardiovasc Med 2002;3:71-76.
3. Rostand RG, Kirk KA, Rutsky EA: Dialysis ischemic heart disease: insight from coronary angiography. Kidney Int 1984;25:653-659.
4. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-1438.
5. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H: Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002;17:1713-1724.
6. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
7. Zimmerman J, Herlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
8. Yeun JY, Levine RA, Mantadilok V, Kayssen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-476.
9. Pecolts-Filho R, Barany P, Linholm B, Heimburger G, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684-1688.
10. Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Marcovina SM, et al: Relationship between C-reactive protein, albumin and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003;42:44-52.
11. Iseki K, Tozawa M, Yoshi S, Fukiyama K: Serum C-reactive protein and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999;14:1956-1960.
12. Heidland A, Sebekov K, Schinkel R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001;38(suppl 1):S100-S106.
13. Bostom AG, Culleton BF: Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999;10:236-244.
14. Kanani PM, Sinkey CA, Browning RL, et al: Role of the oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999;100:1161-1168.
15. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M: Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004;109:369-374.
16. Massy ZA, Nguyen-Khoa T: Oxidative stress and chronic renal failure: markers and management. J Nephrol 2001;12:2742-2752.
17. Wolin MS, Ahmad M, Gupte SA: The sources of oxidative stress in the vessel wall. Kidney Int 2005;67:1659-1661.
18. Galle J: Oxidative stress in chronic renal failure. Nephrol Dial Transplant 2001;16:2135-2137.
19. Ceballos-Picot I, Witko-Sarsta V, Merad-Boudia M, et al: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996;21:845-853.
20. Peuchant E, Delmas-Beauvieux MC, Dubourg L, et al: Antioxidant effects of a supplemented very low protein diet in chronic renal failure. Free Radic Biol Med 1997;22:313-320.
21. Barnes PJ, Karin M: Nuclear factor-κB: a pivotal transcription factor in chronic inflammation disease. N Engl J Med 1997;336:1066-1071.
22. Hoshi S, Goto M, Kyoama N, Nomoto K, Tanaka H: Regulation of vascular smooth muscle cell proliferation by nuclear factor-κB and its inhibitor, I-κB. J Biol Chem 2000;2:883-889.
23. Yudkin JS, Kumari M, Humpfries SE, Mohamed-Ali V: Inflammation obesity stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;14:209-214.
24. Tintut Y, Patel J, Parhami F, Demer LL: Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the camp pathway. Circulation 2000;102:2636-2642.
25. Bhagat K, Valance P: Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997;96:3042-3047.
26. Ungvari Z Csizar A, Kaminski PM: Chronic high pressure induced arterial oxidative stress: involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotension system. Am J Pathol 2004;165:219-226.
27. Barton CH, Ni Z, Vazari ND: Enhanced nitric oxide inactivation an aortic coarctation-induced hypertension. Kidney Int 2001;60:1083-1087.
28. Mervaala EM, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, Vapaato H, Tuiler DN, Fiebeler A, Ganten K, Ganten D, Luft FC: Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 2001;37:414-418.
29. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B: Oxidative stress and endothelial function in chronic renal failure. Am J Soc Nephrol 2001;12:2747-2752.
30. Stenvinkel P, Heimburger O, Paultre F, et al: Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911.
31. Drueke T, Vitko-Sarsat V, Massy Z, et al: Iron therapy, advanced oxidation protein products and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106:2212-2217.
32. Kato A, Takita T, Maruyama Y, Kumagai H, Hishida A: Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int 2003;64:1472-1479.
33. Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM: Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998;32:570-574.
34. Preston E, Ellis MR, Kulinskaya E, Davies AH, Brown EA: Association between carotid intimamedia thickness and cardiovascular risk factors in CKD. Am J Kidney Dis 2005;46:856-862.
35. Boaz M, Smetana S, Weinstein T, et al: Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomised placebo-control trial. Lancet 2000;356:1213-1218.
36. Tepel M, van der Giet M, Statz M, Jankovski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. A randomized, controlled trial. Circulation 2003;107:992-995.
37. Maggi E, Bellagi R, Gazo A, et al: Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869-876.
38. Shoji T, Fukumoto M, Kimoto E, Shinohara K, Emoto M, Tahara H, Koyama H, Ishimura E, Nakatani T, Miki T, Tsujimoto Y, Tabata T, Nishizawa Y: Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int 2002;62:2230-2237.
39. Shoji T, Kimoto E, Shinohara K, Emoto M, Ishimura E, Miki T, Tsujimoto Y, Tabata T, Nishizawa Y: The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients Kidney Int 2003;63(suppl 84):S128-S130.
40. Holvoet P, Donk J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lasaffre E, Vanrenterghem Y, Collen D: Correlation between oxidized low-density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996;76:663-669.
41. Van den Akker J, Bredie SJH, Diepenveen SHA, van Tits LJH, Stalenhoer AFH, Van Leusen R: Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoprotein, C-reactive protein and in vivo oxidizes LDL. J Nephrol 2003;16:238-244.
42. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, et al: Cardiac and arterial interactions in end-stage renal failure. Kidney Int 1996;50:600-608.
43. Davies PF, Tripathi SC: Mechanical stress mechanism and the stress to flow change in the canine carotid artery. Circ Res 1993;235-239.
44. Pohl U, Holtz J, Busse R, Bassenge E: Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986;8:37-44.
45. Tronc F, Wassef M, Esposito B, Henrion D, Glagov S, Tedgui A: Role of NO in flow-induced remodelling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol 1996;16:1256-1262.
46. Langille BL, O'Donnell F: Reduction in arterial diameters produced by chronic decrease in blood flow are endothelium-dependent. Science 1986;231:405-407.
47. Girerd X, London GM, Boutouyrie P, Mourad JJ, Laurent S, Safar M: Remodelling of radial artery and chronic increase in shear stress. Hypertension 1996;27:799-803.
48. Nichols WW, O'Rourke MF: Vascular impedance; in McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles, ed 4. London, Arnold, 1998.
49. London GM, Yaginuma T: Wave reflection: clinical and therapeutic aspect; in Safar ME, O'Rourke MF (eds): The Arterial System in Hypertension. Dordrecht, Kluwer Academic, 1993, pp 221-237.
50. Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM, et al: Creatinine clearance, pulse wave velocity, carotid compliance in essential hypertension. Kidney Int 2001;59:1834-1841.
51. Shinohara K, Shoji T, Tsujimoto Y, Kimoto I, Tahara H, Komana H, et al: Arterial stiffness in predialysis patients with uremia. Kidney Int 2004;65:936-943.
52. Luik AJ, Spek JJ, Charra B, van Bortel L, Laurent G, Leunissen K: Arterial compliance in patients on long-time dialysis. Nephrol Dial Transplant 1997;12:2629-2632.
53. Guerin AP, Pannier B, Marchais S, Metivier F, London GM: Arterial remodelling and cardiovascular function in end-stage renal disease; in Grünfeld JP, Bach JF, Kreiss H, Maxwell MH (eds): Advances in Nephrology. St Louis, Mosby Yearbooks, 1998, vol 27, pp 105-109.
54. Amann K, Neusüa R, Ritz E, Irzyniec T, Wiest G, Mall G: Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 1995;8:409-417.
55. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
56. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial medial calcification in end-stage renal disease impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
57. London GM, Marchais SJ, Guerin AP, Metivier F: Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005;14:525-531.
58. Saito Y, Shirai K Uchino J, Okazawa M, Hattori Y, Yoshida T, et al: Effect of nifedipine administration on pulse wave velocity of chronic hemodialysis patients - two-year trial. Cardiovasc Drug Ther 1990;4:987-990.
59. London GM, Guerin AP, Pannier B, Marchais SJ, Bentos A, Safar ME: Increased systolic pressure in chronic uremia: role of arterial wave reflections. Hypertension 1992;20:10-19.
60. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Colodanoto JA, et al: Association between pulse pressure and mortality in patients undergoing hemodialysis. JAMA 2002;287:1548-1555.
61. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999,99:2434-2439
62. Wever RM, Luscher TF, Cosentino F, Rabelink TJ: Atherosclerosis and the two faces of endothelial nitric oxide synthetase. Circulation 1998;97:108-112.
63. Levy BI, Elfertak L, Pieddeloup C, Barouki F, Safar ME: Role of the endothelium in the mechanical response of the carotid arterial wall to calcium blockade in spontaneously hypertensive and Wistar-Kyoto rats. J Hypertens 1993;11:57-63.
64. Nakanishi T, Ishigami Y, Otaki Y, Izumi M, Hiraoka K, Inoue T, Takamitsu Y: Impairment of vascular response to reactive hyperemia and nitric oxide in chronic renal failure. Nephron 2002;93:529-535.
65. London GM, Pannier B, Agharazii M, Guerin AP, Verbeke FH, Marchais SJ: Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int 2004;65:700-704.
66. Amabile N, Guerin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui A, Boulanger CM: Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005;16:3381-3388.